Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Stevanato Group SpA(STVN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for STVN
09/25/2026: STVN (2-star) is currently NOT-A-BUY. Pass it for now.
Stevanato Group SpA is a prominent provider of advanced containment and delivery solutions for the global pharmaceutical industry. Its business strengths lie in high-quality, pre-sterilized glass containers and sophisticated automation engineering, which build strong, long-term partnerships with leading drug manufacturers. The company's growth story is centered on the ongoing shift in medicine toward biologics and patient self-administration, driving demand for specialized delivery devices. Risks include reliance on large pharmaceutical customers and intense competition in a niche industrial segment. Stevanato is primarily a growth-oriented stock, best suited for investors interested in the healthcare technology supply chain who are willing to monitor execution milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company benefits from long-term secular growth in biologic and self-administration drug delivery markets. |
| Momentum investor | Mixed fit | Performance is subject to industry cycles and news regarding major pharma customer contracts. |
| Value investor | Mixed fit | Valuation often commands a premium due to the company's specialized role in the healthcare supply chain. |
| Dividend investor | Weak fit | The company prioritizes aggressive capital reinvestment for growth over high dividend yields. |
| Low-risk investor | Mixed fit | While essential to the healthcare industry, the stock remains subject to industrial volatility and growth-company valuation swings. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | As a growth-oriented stock in the healthcare supply chain, equity price movements can be sensitive to market sentiment. |
| Valuation risk | Medium | The stock often trades at a premium reflecting its role as a strategic supplier to the pharmaceutical industry. |
| Competition risk (Schott Pharma/BD) | Medium / high | Intense competition for long-term supply contracts with major pharmaceutical companies is a constant pressure. |
| Business quality | Strong | The company holds a strong competitive position in a high-barrier, mission-critical segment of healthcare. |
| Dividend income | Low | Income is not the primary driver for holding this stock; growth and market leadership are prioritized. |
| Execution risk | Medium | Successful scaling of global production facilities is essential to meeting contractual demand and maintaining margins. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -48.73% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.84B USD | Price to earnings Ratio 38.87 | 1Y Target Price 24.68 |
Price to earnings Ratio 38.87 | 1Y Target Price 24.68 | ||
Volume (30-day avg) 378.4K shares | Beta 0.75 | 52 Weeks Range 12.84 - 27.89 | Updated Date 09/25/2026 |
52 Weeks Range 12.84 - 27.89 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.55 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Containment Systems | Glass vials, syringes, and cartridges for pharmaceutical and biotech products. | This is the core, steady business that provides the essential glass packaging for most injectable drugs. |
| Delivery Systems | Autoinjectors, pen injectors, and wearable devices for patient self-administration. | This high-growth segment benefits from the trend of moving drug administration from hospitals to homes. |
| Engineering & Automation | Manufacturing lines and inspection machines for pharmaceutical processes. | This provides necessary support for the company's own production and sells high-tech infrastructure to pharma manufacturers. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 38.87 | Forward PE 29.15 | Enterprise Value 6.34B | Price to Sales(TTM) 4.76 |
Enterprise Value 6.34B | Price to Sales(TTM) 4.76 | ||
Enterprise Value to Revenue 4.52 | Enterprise Value to EBITDA 18.87 | Shares Outstanding 49.83M | Shares Floating 49.03M |
Shares Outstanding 49.83M | Shares Floating 49.03M | ||
Percent Insiders 1.64 | Percent Institutions 97.89 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Stevanato Group SpA
Exchange NYSE | Headquarters Piombino Dese, PD, Italy | ||
IPO Launch date 2021-07-16 | CEO & Executive Chairman Mr. Franco Stevanato | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 6010 | Website https://www.stevanatogroup.com |
Full time employees 6010 | Website https://www.stevanatogroup.com | ||
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.